Compared with placebo, the secondary results of QSYQ's composite clinical events, including all-cause mortality and emergency treatment/hospitalization due to heart failure, were not significantly reduced at 6 months (13% vs. 17%; P = 0.45), and the brain natriuretic peptide changes of QSYQ were not significant either (median changes were −14.55 and −12.30 pg/mL, resp.; P = 0.21). The gene discussed is NPPB; the disease is heart failure.